Share on StockTwits

Portola Pharmaceuticals (NASDAQ:PTLA) CFO Mardi Dier sold 5,000 shares of the company’s stock on the open market in a transaction dated Monday, August 25th. The stock was sold at an average price of $26.26, for a total transaction of $131,300.00. Following the completion of the transaction, the chief financial officer now directly owns 1,118 shares in the company, valued at approximately $29,359. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Zacks upgraded shares of Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Tuesday, August 12th. They now have a $28.30 price target on the stock.

Portola Pharmaceuticals (NASDAQ:PTLA) traded up 7.32% on Monday, hitting $26.84. 249,987 shares of the company’s stock traded hands. Portola Pharmaceuticals has a 52 week low of $19.59 and a 52 week high of $31.48. The stock has a 50-day moving average of $25.59 and a 200-day moving average of $25.25. The company’s market cap is $1.111 billion.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.03. The company had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.44 million. The company’s quarterly revenue was down 7.2% on a year-over-year basis. On average, analysts predict that Portola Pharmaceuticals will post $-3.45 earnings per share for the current fiscal year.

Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.